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1) Yale School of Public Health, 2) Yale School of Medicine, New Haven, CT and 3) University of California Irvine, Irvine, CA, USAAbstractBorrelia miyamotoi is a relapsing fever Borrelia group spirochete that is transmitted by the same hard-bodied (ixodid) tick species that transmit
the agents of Lyme disease. It was discovered in 1994 in Ixodes persulcatus ticks in Japan. B. miyamotoi species phylogenetically cluster with the
relapsing fever group spirochetes, which usually are transmitted by soft-bodied (argasid) ticks or lice. B. miyamotoi infects at least six Ixodes
tick species in North America and Eurasia that transmit Lyme disease group spirochetes and may use small rodents and birds as reservoirs.
Human cases of B. miyamotoi infection were ﬁrst reported in 2011 in Russia and subsequently in the United States, Europe and Japan. These
reports document the public health importance of B. miyamotoi, as human B. miyamotoi infection appears to be comparable in frequency to
babesiosis or human granulocytic anaplasmosis in some areas and may cause severe disease, including meningoencephalitis. The most
common clinical manifestations of B. miyamotoi infection are fever, fatigue, headache, chills, myalgia, arthralgia, and nausea. Symptoms of
B. miyamotoi infection generally resolve within a week of the start of antibiotic therapy. B. miyamotoi infection should be considered in
patients with acute febrile illness who have been exposed to Ixodes ticks in a region where Lyme disease occurs. Because clinical
manifestations are nonspeciﬁc, etiologic diagnosis requires conﬁrmation by blood smear examination, PCR, antibody assay, in vitro
cultivation, and/or isolation by animal inoculation. Antibiotics that have been used effectively include doxycycline for uncomplicated
B. miyamotoi infection in adults and ceftriaxone or penicillin G for meningoencephalitis.
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edu (A.G. Barbour)IntroductionBorrelia miyamotoi is a relapsing fever spirochete transmitted by
the same hard-bodied (ixodid) ticks that are vectors of Borrelia
burgdorferi and other Lyme disease agents [1–10]. As early as
1985, spirochetes that were likely B. miyamotoi were observed
in ticks in the United States. They were mistakenly thought to
be B. burgdorferi as a consequence of cross-reactive antibodies
that were used in direct immunoassays. For example, twoClinical Microbiology and Infection © 2015 The Authors. Published by El
This is an open access artireports identiﬁed putative B. burgdorferi in Ixodes scapularis and
Ixodes paciﬁcus adult ovarial tissue, eggs and/or larvae [11,12].
This led to the false conclusion that B. burgdorferi was trans-
ovarially transmitted by ticks. Recent experimental evidence
has conﬁrmed transovarial (vertical) transmission of
B. miyamotoi but not B. burgdorferi in I. scapularis [13].
Misidentiﬁcation not only led to false conclusions about the
transovarial transmission of B. burgdorferi in Ixodes ticks but may
have delayed recognition of B. miyamotoi as an etiologic agent.
It was not until 1994 that spirochetes identiﬁed as B. miyamotoi
were isolated from ﬁeld-collected Ixodes persulcatus ticks and the
small Japanese ﬁeld mouse Apodemus argenteus in Japan [1]. In
2000 a novel spirochete was serendipitously identiﬁed in
laboratory-reared I. scapularis ticks that were expected to be free
from B. burgdorferi infection. Sequencing of the 16S ribosomal
gene and other loci revealed that this newly discovered organism
from the northeastern United States was closely related to
B. miyamotoi isolates of Japan [2,4]. B. miyamotoi has subsequentlyClin Microbiol Infect 2015; 21: 631–639
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disease and probably occurs throughout much of the Holarctic
region [2–10,13–30]. The discovery of B. miyamotoi expands the
potential geographic range of relapsing fever group Borrelia spe-
cies. Most other relapsing fever spirochetes are transmitted by
soft-bodied ticks (Argasidae) and lice that have different ecologies
and only occasionally are found in the same geographic locations
as Lyme disease vectors [31].
Although the novelty and wide geographic distribution of
B. miyamotoi have been recognized for several years now, this
spirochete received comparatively little attention until human
cases of a relapsing fever– like disease from B. miyamotoi infection
were reported in 2011 in Russia and subsequently in the United
States, Europe and Japan [10,32–38]. These reports have docu-
mented the public health importance of B. miyamotoi. Human
B. miyamotoi infection appears to be comparable in frequency to
babesiosis or human granulocytic anaplasmosis (HGA) in the
northeastern United States and may cause severe disease,
including meningoencephalitis in immunocompromised in-
dividuals, aswell as coinfectionwith other Ixodes-borne pathogens
[10,32–38]. Additionally, antigenic cross-reactivities in immuno-
assays between Borrelia species inNorth America may complicate
diagnosis of both Lyme disease and relapsing fever [39].The organismFIG. 1. Phylograms of aligned syntenic chromosome sequences of nine
selected relapsing fever group and Lyme disease group Borrelia species
by BioNJ neighbor-joining protocol for observed differences at 850,377
ungapped sites by a procedure described elsewhere [44]. Nodes with
bootstrap values of 70% support after 100 replicates are shown. Bar
represents nucleotide substitutions per site. The organisms (with
GenBank accession numbers) were B. miyamotoi strain LB-2001 from
Connecticut, USA (CP006647); B. miyamotoi strain FR64b from Japan
(CP004217); North American tick-borne relapsing fever species
B. turicatae strain 91E135 (CP000049); B. parkeri strain HR1
(CP007022); B. hermsii strain DAH of genomic group I (CP000048);
B. hermsii strain YOR of genomic group II (CP004146); Old World tick-
borne relapsing fever species B. crocidurae strain DOU (CP004267); and
two Lyme disease species, B. burgdorferi strain B31 (AE000783) and
B. afzelii strain PKo (CP002933).B. miyamotoi was not the ﬁrst relapsing fever group species
shown to use a hard-bodied tick species as its primary vector.
The association of the cattle pathogen B. theileri with Boophilus
(now named Rhipicephalus) microplus hard-bodied ticks was
noted by Arnold Theiler a century ago [40]. More recently,
B. lonestari was discovered in Amblyomma species [41], and the
reptile pathogen B. turcica was shown to be transmitted by
Hyalomma species hard-bodied ticks [42]. Nucleotide se-
quences of these organisms, including the complete chromo-
somes of isolates of B. miyamotoi from North America [43] and
Japan (GenBank accession number CP004217), conﬁrmed that
B. miyamotoi and the other hard-bodied tick–associated species
phylogenetically cluster with the relapsing fever Borrelia species
[44]. These include both New World species B. hermsii and
B. turicatae and the Old World species, such as B. crocidurae,
which are transmitted by soft-bodied ticks (Fig. 1). A real-time
quantitative PCR based on the same primers but different
probes for the 16S ribosomal RNA gene distinguishes between
the relapsing fever group species (including B. miyamotoi) and
the Lyme disease group species [45].
Differences exist between B. miyamotoi isolates according to
tick vector and geographic region, but so far, little genetic dif-
ference has been found between isolates within a givenClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licegeographic area or with the same tick vector association
[4,18,29]. The overall genetic difference between a North
American B. miyamotoi isolate (LB-2001) and a Japanese
B. miyamotoi isolate (FR64b) is about the same as between
B. turicatae and B. parkeri, two North American relapsing fever
species with different host and vector associations [31], but less
than between the two major genomic groups of B. hermsii strains
[46] (Fig. 1). In our opinion, the designation sensu lato is provi-
sionally applicable for the North American strains, with sensuEuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 631–639
nses/by-nc-nd/4.0/)
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genetic and phenotypic characterization is carried out [44].
Besides its overall genetic distance from B. burgdorferi and
other Lyme disease species, B. miyamotoi shares with other
relapsing fever group species the distinctive feature of carriage
and expression of a glycerophosphodiester phosphodiesterase
(GlpQ) biosynthetic gene [47]. An antibody response to Borrelia
GlpQ antigen is a characteristic of relapsing fever that distin-
guishes it from the immune response to Lyme disease [47]. On
the other hand, there are many antigenic similarities between
B. miyamotoi and other relapsing fever group species and the
Lyme disease species, which may account for cross-reactive
antibody binding in diagnostic assays based on whole cell anti-
gens [39]. These common antigens include four of the 10 an-
tigens speciﬁed in standard Western blot criteria for Lyme
disease testing [48].
Genetic differences correspond to biologic differences be-
tween B. miyamotoi and the Lyme disease group of disease
agents. As is the case for other relapsing fever group species,
much higher densities of the spirochetes are observed in the
blood of infected wild rodents and laboratory mice than are
observed with Lyme disease species in either natural or
experimental infections [49]. While in vitro cultivation of
B. miyamotoi isolates from Japan was achieved shortly after
discovery, the North American isolates appear to be more
difﬁcult to cultivate than B. burgdorferi (AGB, unpublished
ﬁndings). There are reports of in vitro passage of a North
American isolate in modiﬁed BSK medium that has been used
for other Borrelia species, but the yields of in vitro cultures have
been low to date [50–52]. Transovarial transmission is another
biologic feature that distinguishes B. miyamotoi and several other
relapsing fever species from B. burgdorferi [13].EcologyB. miyamotoi is transmitted to humans by ticks that had acquired
the organism either horizontally from a vertebrate reservoirI. pacificus
I. scapularis
FIG. 2. Approximate current
geographic distributions of the main
tick vectors of Borrelia miyamotoi:
I. scapularis (green) and I. paciﬁcus
(brown) in North America and
I. ricinus (blue) and I. persulcatus (red)
in Eurasia. I. ovatus and I. pavlovskyi
are two other species that have been
shown to carry B. miyamotoi.
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tick. B. miyamotoi has been found in several of the tick species
known to be vectors of Lyme disease group Borrelia species.
These include I. scapularis in the northeastern and north-central
United States and adjoining areas of Canada; Ixodes paciﬁcus in
the far-western United States and British Columbia; Ixodes
ricinus in Europe; and Ixodes persulcatus in Europe and Asia
(Fig. 2) [1–10,14–30]. Ixodes ovatus and Ixodes pavlovskyi in
northern Asia are two other species that have been shown to
carry B. miyamotoi [29]. B. miyamotoi infection rates in ﬁeld-
collected nymphal I. scapularis populations range between
0 and 10% [2,5,7,8,17]. I. paciﬁcus nymph infection rates vary
from 0 to 15% [18,20,21,28]. The ratios of B. burgdorferi to
B. miyamotoi infection in I. scapularis nymphs in the northeastern
United States range from 4:1 to 16:1. In California, the preva-
lence of B. burgdorferi in I. paciﬁcus is approximately tenfold
lower than that observed in the Northeast. Under these cir-
cumstances, B. miyamotoi infection prevalences in nymphal and
adult I. paciﬁcus approach and may exceed those of B. burgdorferi
[20,28]. In Europe, the range of B. miyamotoi infection rates
reported in I. ricinus nymphal ticks is 0 to 3.2%
[3,9,15,16,18,22–26,30]. Infection rates in I. scapularis in Can-
ada and I. persulcatus in Russia fall within the range of
B. miyamotoi infection detected in I. scapularis ticks in the United
States [10,19].
The reservoir hosts of B. miyamotoi throughout much of its
distribution are poorly known or unknown. The white-footed
mouse (Peromyscus leucopus) is a competent reservoir host of
B. miyamotoi in the northeastern United States [2,7], but other
species, including birds [17], also may serve as reservoirs. In a
study of 556 P. leucopus captured in eastern Connecticut,
B. miyamotoi was identiﬁed in the blood of 7% of the mice and in
skin tissue of 2% of mice; the corresponding prevalences for
B. burgdorferi were 12% and 76% in blood and skin of mice [7].
While prevalence of B. miyamotoi was less than for B. burgdorferi,
the densities of B. miyamotoi spirochetes in the blood were
generally much higher than the density of B. burgdorferi spiro-
chetes. Potential B. miyamotoi reservoir host species includeI. ricinus
I. persulcatus 
of European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 631–639
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Japan [25,26,49]. Unlike Lyme disease Borrelia species,
B. miyamotoi are carried by some unfed larvae, the consequence
of transovarial acquisition. If larvae can transmit the infection to
vertebrates, as a report from Japan indicates, then there is the
potential extension of the peak transmission season of certain
species, such as I. scapularis into the later summer, when larval
activity is at its highest [13,29,53].EpidemiologyThere is limited knowledge of the full geographic distribution of
human B. miyamotoi infection, but it is likely to be similar to that
of Lyme disease. Human cases of B. miyamotoi have been re-
ported in Russia, the United States, the Netherlands and Japan.
Two reports of B. miyamotoi seroprevalence have been pub-
lished in healthy residents of southern New England, USA. In
the ﬁrst study, about 1% of 584 archived sera collected from
1990 to 2010 in healthy residents of Block Island, Rhode Island;
Prudence Island, Rhode Island; and Brimﬁeld, Massachusetts,
USA, were seropositive for B. miyamotoi compared with 3% of
277 suspected Lyme disease patients [33]. In the second study,
of 639 sera obtained from healthy residents of southern New
England between 1991 and 2012, 3.9% were B. miyamotoi
seropositive and 9.4% were B. burgdorferi seropositive [34]. A
similar B. miyamotoi seroprevalence rate of 2% was noted in
healthy (blood donor) residents of the Netherlands, while
higher rates were noted in forestry workers (10%), and patients
experiencing HGA (14.6%) and Lyme disease (7.4%) [38].
The geographic range of B. miyamotoi infection in tick vectors
is much broader than the countries where human infection has
been reported. B. miyamotoi has been found in ticks from Asia
(Japan and central Russia), North America (the United States
and Canada) and Europe (Czech Republic, Denmark, England,
Estonia, France, Germany, Netherlands, Poland, Sweden and
Switzerland). It likely coexists with B. burgdorferi or other Lyme
disease Borrelia species throughout its distribution
[1–10,14–30].
B. miyamotoi infections might occur in residents living outside
its known enzootic geographic range through blood transfusion.
Recurrent high-density spirochetemia is characteristic of re-
lapsing fever and increases the risk of transfusion transmission.
Transfusion-transmitted relapsing fever caused by Borrelia
recurrentis and Borrelia duttonii have been reported [54–56]. A
recent study showed that B. miyamotoi can be transmitted
through blood transfusion in a mouse experimental model [57].
Motile spirochetes were observed microscopically in the blood
of both immunocompromised and immunocompetent mouse
recipients after transfusion of murine B. miyamotoi– infectedClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceblood that was either fresh or stored for seven days under
conditions used in human blood banks. Spirochetemia was
observed in immunocompetent mice up to ﬁve days and in
immunocompromised mice 28 days after transfusion with fresh
or stored B. miyamotoi– infected blood. These data suggest that
transfusion transmission of B. miyamotoi may occur in humans.Clinical manifestationsThe most commonly reported clinical presentation of
B. miyamotoi infection is a febrile illness consisting of a tem-
perature that may exceed 40°C, fatigue, headache, chills,
myalgia, arthralgia and nausea (Table 1). In the ﬁrst reported
case series of B. miyamotoi infection, patients were enrolled
who had a history of recent tick bite [10]. Five (11%) of the 46
B. miyamotoi patients experienced two to three episodes of
fever, each lasting two to ﬁve days with a mean interval of
nine days between episodes (range two days to two weeks).
The frequency of cases of relapse of illness might have been
higher if most patients had not been provided empiric antibiotic
therapy during their ﬁrst episode of fever. The fever associated
with B. miyamotoi infection generally lasts less than a week, even
without antibiotic therapy, while other symptoms such as fa-
tigue may persist for as long as several weeks after antibiotic
therapy [32–37]. The course of relapsing fever transmitted by
soft-bodied ticks is similar. It generally consists of two or more
episodes of fever lasting one to ﬁve days, each with intervals of
well-being lasting at least two days and no more than seven days
between febrile episodes in untreated patients [58]. Patients
infected with relapsing fever spirochetes have experienced as
many as six episodes of recurrent fever [58]; the maximum
noted with B. miyamotoi thus far is three episodes [10].
In contrast to the clinical course of the majority of reported
B. miyamotoi cases, two patients with well-documented
B. miyamotoi infections of the central nervous system experi-
enced symptoms and signs of meningoencephalitis. They each
experienced a progressive decline in cognition and unsteady gait
over several months but had no fever [32,35]. One was an 80-
year-old woman from the United States, and the other was a
70-year-old man from the Netherlands. Both had a lympho-
proliferative disorder (non-Hodgkin lymphoma and diffuse large
B cell lymphoma, respectively) and had received chemotherapy
that was discontinued six months or more before the onset of
symptoms. The diagnosis of B. miyamotoi infection was
conﬁrmed in both cases by cerebrospinal ﬂuid (CSF) analysis,
which showed spirochetes on Giemsa staining of a cytospin of
CSF sediment or direct dark-ﬁeld examination of CSF,
increased white blood cell count and protein, and ampliﬁcation
and sequencing of B. miyamotoi DNA. The patient in the UnitedEuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 631–639
nses/by-nc-nd/4.0/)
TABLE 1. Clinical manifestations in patients with Borrelia spp. infection, Yekaterinburg City, Russia, 2009, and northeastern United
States, 1991–2008
Manifestation
% Patients p
B. miyamotoi
(n [ 46)
B. garinii
(n [ 21)
B. burgdorferi
(n [ 92)
B. miyamotoi vs.
B. garinii
B. miyamotoi vs.
B. burgdorferi
B. garinii vs.
B. burgdorferi
Individual
EM 9 91 89 <0.001 <0.001 >0.999
Multiple EM 0 14 7 0.03 0.18 0.36
Fever* 98 67 32 0.001 <0.001 0.005
Fatigue 98 86 74 0.09 <0.001 0.4
Headache 89 57 63 0.007 0.001 0.63
Chills 35 10 43 0.04 0.36 0.005
Myalgia 59 52 63 0.8 0.71 0.46
Arthralgia 28 29 62 >0.999 <0.001 0.007
Nausea 30 10 24 0.07 0.420 0.24
Vomiting 7 5 7 >0.999 >0.999 >0.999
Neck stiffness 2 0 38 >0.999 <0.001 <0.001
Overall
No. symptoms, mean ± SD 4.5 ± 1.4 4.2 ± 2.0 5.0 ± 2.3 0.43 0.13 0.13
No. symptoms excluding EM and multiple
EM, mean ± SD
4.5 ± 1.4 3.1 ± 1.9 4.1 ± 2.3 0.007 0.46 0.09
Adapted from Platonov AE, Karan LS, Kolyasnikova NM, Makhneva NA, Toporkova MG, Maleev VV, Fish D, Krause PJ. Humans infected with relapsing fever spirochete Borrelia
miyamotoi, Russia. Emerg Infect Dis 2011; 17:1816–1823 [10].
EM, erythremia migrans.
*Maximum axillary temperature >37.2°C for patients in Russia and maximum oral temperature >37.7°C for patients in the United States.
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intravenous penicillin. The patient from the Netherlands was
provided two weeks of ceftriaxone. Both patients experienced
a full recovery, including recovery of neurologic function, a
month after the start of antibiotic therapy.
B. miyamotoi and B. burgdorferi coinfection has been docu-
mented in reports from the United States and Japan [34,37]. In
the Russian B. miyamotoi case series, nine of 46 cases had an
erythema migrans rash. Although there was no conﬁrmation,
B. burgdorferi coinfection was the most likely cause because
erythema migrans rash has not been associated with soft-
bodied tick–transmitted relapsing fever [10,58]. Previous
studies have shown that coinfections of B. burgdorferi with
either Babesia microti or with Anaplasma phagocytophilum are
associated with more severe disease compared with that
B. burgdorferi infection alone [59–61]. Further studies with a
large sample size will be needed to determine whether
B. miyamotoi and B. burgdorferi coinfection inﬂuences the
outcome of disease in humans.DiagnosisDiagnosis of B. miyamotoi infection should be considered in any
patient who resides in or has recently traveled to a region
where Lyme disease is endemic in the North American or
Eurasian continents during tick disease transmission season and
who develops fever. Unlike Lyme disease, babesiosis, and HGA,
it is conceivable that B. miyamotoi infection can be acquired by
humans from the bite of a larval tick because of transovarial
transmission [29]. Consistent clinical ﬁndings such as fever,Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf
This is an open access artifatigue and headache provide support for the diagnosis, but
similar symptoms may occur with other Ixodes-transmitted
diseases (such as Lyme disease, babesiosis, HGA, tick-borne
encephalitis in Eurasia and deer tick virus encephalitis in
North America) and acute viral infections. Diagnosis therefore
requires conﬁrmation using speciﬁc laboratory tests that
include blood smear, PCR, and/or antibody determination
[10,32–38]. At least one commercial laboratory is offering an
antibody and a PCR test for B. miyamotoi, and these tests are
likely to be available in the near future from other commercial
companies. B. miyamotoi can be isolated following in vitro culture
or inoculation into immunodeﬁcient laboratory mice, but these
methods are conﬁned to a limited number of research
laboratories.
If the density of spirochetes in the blood is 104 per milli-
liter, B. miyamotoi might be identiﬁed by examining several high-
power ﬁelds of a thin blood smear or a spun sample of cere-
brospinal ﬂuid (for those suspected of having meningitis or
meningoencephalitis) stained with Giemsa or Wright stain. The
blood smear used for a manual white blood cell differential will
serve. A thick smear, such as prepared for a malaria screen, that
has been dehemoglobinized and then stained with acridine or-
ange, may reveal spirochetes present at lower densities in the
blood. Motile spirochetes may be detected by dark-ﬁeld or
phase contrast of a wet mount of anticoagulated blood mixed
with an equal volume of physiologic saline (Fig. 3).
Several PCR assays have been described for the detection of
B. miyamotoi in whole blood, plasma, CSF and tissues using
primers speciﬁc for 16S ribosomal RNA and for the ﬂaB and
glpQ genes [3,7,32,35]. One of these discriminates between the
Lyme disease and relapsing fever groups of Borrelia species, isof European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 631–639
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
FIG. 3. (A) B. miyamotoi grown
in vitro (phase contrast; original
magniﬁcation, 100 × ; scale bar = 5
μm). (B) B. miyamotoi grown in vitro
(dark ﬁeld; original magniﬁcation,
40 × ; scale bar = 15 μm). (C)
B. miyamotoi in infected mouse blood
(phase contrast of wet mount of
plasma; original magniﬁcation, 400×).
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in ticks and in animal blood and tissues [7]. In vitro cultivation of
B. miyamotoi isolates from Japan and North America have been
achieved in specialized media, but the reported yields of cul-
tures for a North American isolate were lower than that ex-
pected for B. burgdorferi and several other Borrelia species
[50–52].
Serologic testing can help conﬁrm B. miyamotoi diagnosis. A
two-tiered antibody assay based on recombinant B. miyamotoi
GlpQ protein has been developed that detects GlpQ-speciﬁc
antibodies during the acute and convalescent stages of infec-
tion [33,34,47]. B. miyamotoi GlpQ protein is no more than 50%
identical to the GlpQ proteins of some other bacterial patho-
gens, such as Klebsiella pneumoniae and Salmonella enterica. On
the basis of this distance, B. miyamotoi GlpQ is not expected to
cross-react with anti-GlpQ antibodies elicited by other disease
agents, but this has not been established as yet. More clinically
relevant is the presumption that sera from Lyme disease pa-
tients will not cross-react in a GlpQ assay because Lyme disease
Borrelia species (as well as Anaplasma, Babesia and Ehrlichia
species) lack the gene for GlpQ [47]. In contrast, the sera of
10% of B. miyamotoi infected patients met the criteria for
seropositivity in a standard two-tier B. burgdorferi antibody
assay [34]. Possible causes included a prior B. burgdorferi
infection, acute coinfection with B. burgdorferi, a false-positive
test reaction and/or cross-reactivity of antibodies elicited byClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licethe B. miyamotoi infection against one or more B. burgdorferi
antigens. The results of whole cell B. burgdorferi enzyme
immunoassay tests were positive in some patients who appar-
ently had B. miyamotoi alone, possibly due to cross-reactivity of
B. miyamotoi–elicited antibodies with some B. burgdorferi pro-
teins [10,34]. B. miyamotoi genes encode the homologues of
many B. burgdorferi proteins, including the ﬂagellin FlaB protein,
GroEL heat shock proteins, P66 outer membrane protein and
the BmpA (P39)-type basic membrane protein. B. miyamotoi
antibody probably cross-reacts with the GlpQ proteins of other
relapsing fever Borrelia species, as well as B. lonestari. These
organisms are not transmitted by Ixodes ticks and generally have
different areas of distribution than B. miyamotoi in North
America and Eurasia, although there are some areas in Cali-
fornia where both B. miyamotoi and B. hermsii are enzootic
[34,47,58].
The development of a method to grow cultures of
B. miyamotoi strains in vitro provides an opportunity to identify
additional antigenic B. miyamotoi proteins that would not be
expected to cross-react with Lyme disease Borrelia antigens or
other clinically relevant etiologic agents [43,50–52]. The data-
base of the deduced proteins from the genome sequences
provides a basis for identifying informative antigens that are
expressed in vivo but not in vitro, as was carried with a genome-
wide protein array for B. burgdorferi [62]. If the immunodo-
minant antigens during B. miyamotoi infection include theEuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 631–639
nses/by-nc-nd/4.0/)
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variation during relapsing fever from other species [62], then
there may need to be several variant antigens in a microarray-
based or bead-based assay to detect the spectrum of antibody
responses in infected patients.Treatment and preventionTreatment recommendations for B. miyamotoi infection are
based on the few case reports and series that have been pub-
lished thus far and supplemented here by the recommendations
for treatment of other relapsing fever Borrelia infections
[10,32–37,58]. There have been no therapeutic trials or
experimental data published on the antibiotic susceptibility
either in vitro or in vivo of B. miyamotoi. Therefore, optimal
antibiotics of choice, their dosages and treatment duration have
yet to be determined.
Doxycycline (100 mg orally every 12 hours) provided for
seven to 14 days is the most commonly prescribed antibiotic for
patients experiencing uncomplicated B. miyamotoi infection to
date [10,32–37]. This tetracycline appears to have been effective
based on fever defervescence within ﬁve days of initiation and
absence of further fever episodes. Intravenous ceftriaxone (2 g
once a day) provided for two weeks or penicillin G (24 million U
per day) provided for four weeks were used successfully in two
patients with meningoencephalitis [32,35].
Amoxicillin or cefuroxime provided orally are suitable al-
ternatives to doxycycline or other tetracyclines, which are
generally contraindicated for children younger than nine years
of age and for pregnant and nursing women. These antibiotics
are commonly used for treatment of Lyme disease and would
be expected to be effective against B. miyamotoi infection based
on susceptibilities of other relapsing fever Borrelia species.
Penicillin G or cefotaxime are alternatives to ceftriaxone for
parenteral therapy of documented or suspected central ner-
vous system involvement or other severe infection. Azi-
thromycin would also probably clear infection, but macrolides
are generally less effective than tetracyclines and most β-lactam
antibiotics for Borrelia infections. Some ﬁrst-generation cepha-
losporins such as cephalexin are likely not as effective against
B. miyamotoi as other β-lactam antibiotics. On the basis of other
Borrelia species, B. miyamotoi is likely to be relatively resistant to
ﬂuoroquinolones and aminoglycosides. If HGA is suspected,
then doxycycline, but not β-lactam antibiotics or macrolides,
would probably be effective for both infections.
The Jarisch-Herxheimer reaction is a commonly encoun-
tered mild to serious adverse effect of the ﬁrst dose or two of
antibiotic therapy for relapsing fever [58,63]. The fever returns
or increases to a temperature of 40°C. There are
Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf
This is an open access artiaccompanying chills and rigors followed by diaphoresis. Hypo-
tension and a shocklike state may occur suddenly and be life-
threatening. It has been reported in up to half of people pro-
vided antibiotics for tick-borne relapsing fever and 15% of
people treated for B. miyamotoi infection in Russia [10,58]. A
patient from the United States experiencing meningoencepha-
litis developed manifestations of a Jarisch-Herxheimer reaction,
including hypotension, within nine hours after her initial dose of
ceftriaxone [32]. Effective management of this problem includes
anticipation of the reaction with the initiation of antibiotics and
the provision of monitoring and supportive measures, such as
volume expansion and antipyretics.
Effective preventive measures for B. miyamotoi infection are
expected to be the same as for other Ixodes tick-borne diseases,
such as Lyme disease. They include personal protective mea-
sures to avoid tick bite, landscape modiﬁcation and environ-
mental measures to reduce tick abundance. No vaccine has
been developed and approved for B. miyamotoi or any other
relapsing fever Borrelia species.SummaryB. miyamotoi is a recently discovered human pathogen belonging
to the relapsing fever group of species in the spirochete genus of
Borrelia. It is transmitted by the samehard-bodied tick species that
are the vectors of Lyme disease and is likely to be foundwherever
Lyme disease occurs. Human infection has been shown to be
prevalent in the northeastern United States. Disease severity is
variable, but patients most commonly present with fever and
nonlocalizing symptoms. Meningoencephalitis requiring hospital
admission has been reported. There is limited availability of lab-
oratory testing for infection at this time. Laboratory procedures
that can be widely implemented but are of uncertain sensitivity
include examination of a stained blood smear for spirochetes and
ampliﬁcation of B. miyamotoiDNAusing PCR. Assays of acute and
convalescent sera for antibodies to the GlpQ protein of
B. miyamotoi may provide conﬁrmation of a diagnosis; other im-
munoassays are in development. Procedures with very limited
availability for direct detection are in vitro cultivation and animal
inoculation. The most common antimicrobial agents that have
been used to achieve cure are doxycycline and ceftriaxone, but
other antibiotics that are used to treat tick-borne relapsing fever
and Lyme disease are likely to be as effective as well.Transparency declarationAll authors report no conﬂicts of interest relevant to this
article.of European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 631–639
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